[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601739":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":26,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":26,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":63,"minAge":64,"maxAge":26,"enrollmentInfo":65,"targetDuration":26,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":26,"overallStatus":77,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Pharmbio Korea Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","PBK\\_M2502, 1-Day Regimen",[13],"Drug: PBK_M2502 1-Day",{"label":15,"type":16,"description":17,"interventionNames":18},"active Comparator","ACTIVE_COMPARATOR","PBK\\_M2502, 2-Day Regimen",[19],"Drug: PBK_M2502 2-Day",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","PBK_M2502 1-Day","Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"PBK_M2502 2-Day","Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Manager Clinical Trial team, Pharmbio Korea","CONTACT","+82-2-587-2551","cr@pharmbio.co.kr",[38],{"facility":39,"status":26,"city":40,"state":41,"zip":26,"country":42,"countryCode":26,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Kyung Hee University Hospital at Gangdong","Seoul","Gangdong-gu","South Korea",{"type":44,"coordinates":45},"Point",[46,47],126.9784,37.566,{"lat":47,"lon":46},[50],{"name":51,"role":52,"phone":26,"phoneExt":26,"email":26},"Cha Jaemyung, Principal Investigator","PRINCIPAL_INVESTIGATOR",{"type":54,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100601739","phase-3-a-study-to-evaluate-safety-and-efficacy-of-pbkm2502-100601739",false,"NCT07114406","A Study to Evaluate Safety and Efficacy of PBK_M2502","A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK_M2502","Inclusion Criteria:\n\n* Patients who is informed and give a consent in voluntary\n* Patients who is scheduled a esophagogastroduodenoscopy and colonoscopy\n* BMI 19≤and\\\u003C30\n\nExclusion Criteria:\n\n* Patients who participate in other interventional study or had participated within 30 days before screening\n* Pregnant or breast-feeding women who do not want to stop breast-feeding\n* Uncontrolled hypertension\n* Uncontrolled diabetes\n* Fluid or electrolyte (Na, K, Ca, Mg, chloride, bicarbonate) disturbance\n* HIV infection and\u002For chronic hepatitis B or C\n* Patients who has a difficulty to participate because of severe nausea or vomiting\n* History of colon surgery and abdominal surgery within 6 month; need an emergency surgery",true,"ALL","19 Years",{"count":66,"type":67},110,"ESTIMATED","INTERVENTIONAL",[70],"PHASE3","This clinical trial was prospective, randomized, single-blind, 3-treatment arm, parallel treatment group, and active-controlled. , Multi-center, Phase 3 confirmatory clinical trial.",[73,74,75,76],"Intestinal Disease","Colonic Diseases","Gastrointestinal Disease","Digestive System Disease","NOT_YET_RECRUITING","2025-08-03",{"date":80,"type":81},"2025-08-11","ACTUAL",{"date":83,"type":67},"2025-08",{"date":85,"type":67},"2026-11",{"name":5,"class":6},1]